First-Line Systemic Therapy Practice Patterns and Concordance With NCCN Guidelines for Patients Diagnosed With Metastatic NSCLC Treated at NCCN Institutions

Restricted access

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) allow many systemic therapy options for patients with metastatic non–small cell lung cancer (NSCLC). This analysis uses the NCCN NSCLC Outcomes Database to report on first-line therapy practice patterns and concordance with NCCN Guidelines. The analysis was limited to patients diagnosed with metastatic NSCLC between September 2006 and November 2009 at 1 of 8 participating NCCN Member Institutions. Patient characteristics, regimens used, and guidelines concordance were analyzed. Institutional variation and changes in practice over time were also measured. A total of 1717 patients were included in the analysis. Of these, 1375 (80%) were treated with systemic therapy, most often in the form of a carboplatin-based doublet (51%) or carboplatin-based doublet with targeted therapy (17%). Overall, 76% of patients received care that was concordant with NCCN Guidelines. Among patients with good performance status (n = 167), the most common reasons for not receiving first-line therapy were that therapy was not recommended (39%) or death occurred before treatment (33%). The most common reason for receiving nonconcordant drug therapy was the administration of pemetrexed or erlotinib before its incorporation into the NCCN Guidelines for first-line therapy (53%). Most patients in this cohort received care that was concordant with NCCN Guidelines. The NSCLC Outcomes Database is a valuable resource for evaluating practice patterns and concordance with NCCN Guidelines among patients with NSCLC.

Correspondence: Carrie Zornosa, MSPH, National Comprehensive Cancer Network, 275 Commerce Drive, Suite 300, Fort Washington, PA 19034. E-mail: zornosa@nccn.org
  • 1

    SiegelRNaishadhamDJemalA. Cancer statistics, 2012. CA Cancer J Clin2012;62:1029.

  • 2

    RiesLAYoungJLKeelGE eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer InstituteSEER Program; 2007. Available at: http://seer.cancer.gov/publications/survival/seer_survival_mono_lowres.pdf. Accessed April 25 2012.

    • Search Google Scholar
    • Export Citation
  • 3

    EttingerDSAkerleyWBorghaeiH. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 32012. Available at NCCN.org. Accessed June 1 2012.

    • Search Google Scholar
    • Export Citation
  • 4

    GreeneFL ed. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual6th ed.New York, NY: Springer; 2002.

  • 5

    EttingerDSAkerleyWBeplerG. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 12007. For the most recent and complete version of these guidelines visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 6

    EttingerDSAkerleyWBeplerG. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 12008. For the most recent and complete version of these guidelines visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 7

    EttingerDSAkerleyWBeplerG. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 12009. For the most recent and complete version of these guidelines visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 8

    ShermanSLWaldingerMBPaulDE. The 2010 National Comprehensive Cancer Network (NCCN) research benchmarking survey (RBS): clinical trials in the academic cancer center [abstract]. J Clin Oncol2011;29(Suppl):Abstract 6116.

    • Search Google Scholar
    • Export Citation
  • 9

    DelbaldoCMichielsSSyzN. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA2004;292:470484.

    • Search Google Scholar
    • Export Citation
  • 10

    ScagliottiGVParikhPvon PawelJ. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol2008;26:35433551.

    • Search Google Scholar
    • Export Citation
  • 11

    D'AddarioGPintilieMLeighlNB. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol2005;23:29262936.

    • Search Google Scholar
    • Export Citation
  • 12

    RajeswaranATrojanABurnandBGiannelliM. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer2008;59:111.

    • Search Google Scholar
    • Export Citation
  • 13

    EberhardDAJohnsonBEAmlerLC. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol2005;23:59005909.

    • Search Google Scholar
    • Export Citation
  • 14

    GatzemeierUPluzanskaASzczesnaA. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol2007;25:15451552.

    • Search Google Scholar
    • Export Citation
  • 15

    HerbstRSPragerDHermannR. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol2005;23:58925899.

    • Search Google Scholar
    • Export Citation
  • 16

    SequistLVJoshiVAJannePA. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist2007;12:9098.

    • Search Google Scholar
    • Export Citation
  • 17

    TsaoMSSakuradaACutzJC. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med2005;353:133144.

  • 18

    MokTSWuYLThongprasertS. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med2009;361:947957.

  • 19

    RosellRGervaisRVergnenegreA. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial [abstract]. J Clin Oncol2011;29(Suppl):Abstract 7503.

    • Search Google Scholar
    • Export Citation
  • 20

    EttingerDSAkerleyWBeplerG. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 12010. For the most recent and complete version of these guidelines visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 21

    SEER Cancer Statistics Review1975-2008. Table 1.11. National Cancer Institute Web site. Available at: http://seer.cancer.gov/csr/1975_2008/results_single/sect_01_table.11_2pgs.pdf. Accessed April 25 2012.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 121 120 10
PDF Downloads 25 25 6
EPUB Downloads 0 0 0